Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;99:2371-2377

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mahaffey, K. W.
Right arrow Articles by Califf, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahaffey, K. W.
Right arrow Articles by Califf, R. M.
Related Collections
Right arrow Acute coronary syndromes
Right arrow Risk Factors for Stroke

(Circulation. 1999;99:2371-2377.)
© 1999 American Heart Association, Inc.


Clinical Investigation and Reports

Stroke in Patients With Acute Coronary Syndromes

Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial

Kenneth W. Mahaffey, MD; Robert A. Harrington, MD; Maarten L. Simoons, MD; Christopher B. Granger, MD; Carmelo Graffagnino, MD; Mark J. Alberts, MD; Daniel T. Laskowitz, MD; Julie M. Miller, MD; Michael A. Sloan, MD; Lisa G. Berdan, PA-C, MHS; Cynthia M. MacAulay, MS; A. Michael Lincoff, MD; Jaap Deckers, MD; Eric J. Topol, MD; Robert M. Califf, MD; for the PURSUIT Investigators

From Duke Clinical Research Institute, Durham, NC (K.W.M., R.A.H., C.B.G., C.G., M.J.A., D.L., J.M.M., L.G.B., C.M.M., R.M.C.); Harbin Clinic, Rome, Ga (M.A.S.); Thorax Center, Erasmus University, Rotterdam, The Netherlands (M.L.S., J.D.); and The Cleveland Clinic Foundation, Cleveland, Ohio (A.M.L., E.J.T.).

Correspondence to Kenneth W. Mahaffey, MD, PO Box 17969, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705. E-mail mahaf002{at}mc.duke.edu

Background—The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates.

Methods and Results—We studied the 10 948 patients with acute coronary syndromes without persistent ST-segment elevation who were randomly assigned to placebo or the platelet glycoprotein IIb/IIIa receptor inhibitor eptifibatide in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial to determine stroke rates, stroke types, clinical outcomes in patients with stroke, and independent baseline clinical predictors for nonhemorrhagic stroke. Stroke occurred in 79 (0.7%) patients, with 66 (0.6%) nonhemorrhagic, 6 intracranial hemorrhages, 3 cerebral infarctions with hemorrhagic conversion, and 4 of uncertain cause. There were no differences in stroke rates between patients who received placebo and those assigned high-dose eptifibatide (odds ratios and 95% confidence intervals 0.82 [0.59, 1.14] and 0.70 [0.49, 0.99], respectively). Of the 79 patients with stroke, 17 (22%) died within 30 days, and another 26 (32%) were disabled by hospital discharge or 30 days, whichever came first. Higher heart rate was the most important baseline clinical predictor of nonhemorrhagic stroke, followed by older age, prior anterior myocardial infarction, prior stroke or transient ischemic attack, and diabetes mellitus. These factors were used to develop a simple scoring nomogram that can predict the risk of nonhemorrhagic stroke.

Conclusions—Stroke was an uncommon event in patients with acute coronary syndromes in the PURSUIT trial. These strokes are, however, associated with substantial morbidity and mortality rates. The majority of strokes were of nonhemorrhagic causes. Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed. We developed a useful nomogram for assigning baseline nonhemorrhagic stroke risk in this patient population.


Key Words: stroke • coronary disease • myocardial infarction • glycoproteins • receptors




This article has been cited by other articles:


Home page
StrokeHome page
A. M. Pancioli, J. Broderick, T. Brott, T. Tomsick, J. Khoury, J. Bean, G. del Zoppo, D. Kleindorfer, D. Woo, P. Khatri, et al.
The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke: The CLEAR Stroke Trial
Stroke, December 1, 2008; 39(12): 3268 - 3276.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R D Lopes, K S Pieper, J R Horton, S M Al-Khatib, L K Newby, R H Mehta, F Van de Werf, P W Armstrong, K W Mahaffey, R A Harrington, et al.
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
Heart, July 1, 2008; 94(7): 867 - 873.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, M. Szarek, D. D. Waters, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress
Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study
Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 142 - 147.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. D. Wiviott, E. Braunwald, C. H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.-J. Neumann, D. Ardissino, S. De Servi, S. A. Murphy, et al.
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
N. Engl. J. Med., November 15, 2007; 357(20): 2001 - 2015.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al.
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Circulation, June 20, 2006; 113(24): e873 - e923.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al.
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Stroke, June 1, 2006; 37(6): 1583 - 1633.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
Additional Information
JAMA, March 15, 2006; 295(11): E7 - E14.
[Full Text] [PDF]


Home page
Eur Heart JHome page
K. E. Szummer, S. D. Solomon, E. J. Velazquez, R. Kilaru, J. McMurray, J.-L. Rouleau, K. W. Mahaffey, A. P. Maggioni, R. M. Califf, M. A. Pfeffer, et al.
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
Eur. Heart J., October 2, 2005; 26(20): 2114 - 2119.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Budaj, K. Flasinska, J. M. Gore, F. A. Anderson Jr, O. H. Dabbous, F. A. Spencer, R. J. Goldberg, K. A.A. Fox, and for the GRACE Investigators
Magnitude of and Risk Factors for In-Hospital and Postdischarge Stroke in Patients With Acute Coronary Syndromes: Findings From a Global Registry of Acute Coronary Events
Circulation, June 21, 2005; 111(24): 3242 - 3247.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Hanefeld, C. Sirtl, M. Spiecker, W. Bojara, P. H. Grewe, T. Lawo, and A. Mugge
Prehospital Therapy With the Platelet Glycoprotein IIb/IIIa Inhibitor Eptifibatide in Patients With Suspected Acute Coronary Syndromes: The Bochum Feasibility Study
Chest, September 1, 2004; 126(3): 935 - 941.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Savonitto, P.W. Armstrong, A.M. Lincoff, G. Jia, C.A. Sila, J. Booth, P. Terrosu, C. Cavallini, H.D. White, D. Ardissino, et al.
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial
Eur. Heart J., October 2, 2003; 24(20): 1807 - 1814.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. D. Waters, G. G. Schwartz, A. G. Olsson, A. Zeiher, M. F. Oliver, P. Ganz, M. Ezekowitz, B. R. Chaitman, S. J. Leslie, T. Stern, et al.
Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy
Circulation, September 24, 2002; 106(13): 1690 - 1695.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis
Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4666 - 4673.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Cronin, S. R. Mehta, F. Zhao, J. Pogue, A. Budaj, D. Hunt, and S. Yusuf
Stroke in Relation to Cardiac Procedures in Patients With Non-ST-Elevation Acute Coronary Syndrome: A Study Involving >18 000 Patients
Circulation, July 17, 2001; 104(3): 269 - 274.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. M. Akkerhuis, J. W. Deckers, A. M. Lincoff, J. E. Tcheng, E. Boersma, K. Anderson, C. Balog, R. M. Califf, E. J. Topol, and M. L. Simoons
Risk of Stroke Associated With Abciximab Among Patients Undergoing Percutaneous Coronary Intervention
JAMA, July 4, 2001; 286(1): 78 - 82.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al.
Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association
Circulation, January 2, 2001; 103(1): 163 - 182.
[Full Text] [PDF]


Home page
StrokeHome page
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al.
Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association
Stroke, January 1, 2001; 32(1): 280 - 299.
[Full Text] [PDF]


Home page
JAMAHome page
D. L. Bhatt and E. J. Topol
Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
JAMA, September 27, 2000; 284(12): 1549 - 1558.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R.A. Harrington and M.L. Simoons
What have we learned from the recent large trials in acute coronary syndromes without ST-segment elevation?
Eur. Heart J., May 1, 2000; 21(9): 702 - 704.
[PDF]


Home page
J Am Coll CardiolHome page
C. P. Cannon
Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1395 - 1402.
[Abstract] [Full Text] [PDF]


Home page
JWatch Emergency Med.Home page
Stroke in Unstable Angina: Uncommon but Serious
Journal Watch Emergency Medicine, July 1, 1999; 1999(701): 15 - 15.
[Full Text]